EUVIMEDEUVIMED entdecken
Crossref

CAR-Macrophage Therapy Alleviates Myocardial Ischemia-Reperfusion Injury

Jiawan Wang iD, Heng Du iD, Wanrun Xie iD, Jinmiao Bi iD, Hao Zhang iD, Xu Liu iD, Yuhan Wang, Shaolong Zhang, Anhua Lei, Chuting He, Hailong Yuan, Jiahe Zhang iD und 13 weitere

Circulation Research · 06.12.2024 · 135 (12) · 1161-1174

DOI: 10.1161/circresaha.124.325212 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Circulation Research, erschienen am 06.12.2024. Verfasst von Jiawan Wang und 24 weiteren Autor:innen. Beteiligte Einrichtung: Key Laboratory of Organ Regeneration and Reconstruction, State Key Laboratory of Membrane Biology, Institute of Zoology, Chinese Academy of Sciences,…. Hauptthemen laut MEDLINE: Myocardial Reperfusion Injury, Macrophages, Fibroblasts, Fibrosis. Die Arbeit wurde bisher 93-mal zitiert (Crossref) und nennt 43 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Given the growing acknowledgment of the detrimental effects of excessive myocardial fibrosis on pathological remodeling after myocardial ischemia-reperfusion injury (I/R), targeting the modulation of myocardial fibrosis may offer protective and therapeutic advantages. However, effective clinical interventions and therapies that target myocardial fibrosis remain limited. As a promising chimeric antigen receptor (CAR) cell therapy, whether CAR macrophages (CAR-Ms) can be used to treat I/R remains unclear. METHODS: The expression of FAP (fibroblast activation protein) was studied in mouse hearts after I/R. FAP CAR-Ms were generated to target FAP-expressing cardiac fibroblasts in mouse hearts after I/R. The phagocytosis activity of FAP CAR-Ms was tested in vitro. The efficacy and safety of FAP CAR-Ms in treating I/R were evaluated in vivo. RESULTS: FAP was significantly upregulated in activated cardiac fibroblasts as early as 3 days after I/R. Upon demonstrating their ability to engulf FAP-overexpressing fibroblasts, we intravenously administered FAP CAR-Ms to mice at 3 days after I/R and found that FAP CAR-Ms significantly improved cardiac function and reduced myocardial fibrosis in mice after I/R. No toxicities associated with FAP CAR-Ms were detected in the heart or other organs at 2 weeks after I/R. Finally, we found that FAP CAR-Ms conferred long-term cardioprotection against I/R. CONCLUSIONS: Our proof-of-concept study demonstrates the therapeutic potential of FAP CAR-Ms in alleviating myocardial I/R and potentially opens new avenues for the treatment of a range of heart diseases that include a fibrotic phenotype.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Myocardial Reperfusion InjuryMacrophagesFibroblastsFibrosisMice, Inbred C57BLEndopeptidasesAnimalsMiceMaleReceptors, Chimeric AntigenMyocardiumMembrane ProteinsGelatinasesSerine EndopeptidasesPhagocytosisCells, CulturedFibroblast Activation Protein Alpha

Stichwörter der Autor:innen

cardiomyopathiesfibrosismacrophagesmyocardial reperfusion injuryreceptors, chimeric antigen

Substanzen

EndopeptidasesReceptors, Chimeric AntigenMembrane ProteinsGelatinasesSerine EndopeptidasesFibroblast Activation Protein Alpha

Autor:innen und Institutionen

  • Key Laboratory of Organ Regeneration and Reconstruction, State Key Laboratory of Membrane Biology, Institute of Zoology, Chinese Academy of Sciences, Beijing, China (J. Wang, H.D., J.B., H.Z., X.L., Y.W., C.H., H.Y., Ji…
  • University of Chinese Academy of Sciences, Beijing, China (J. Wang, H.D., J.B., H.Z., X.L., Y.W., C.H., H.Y., Jiahe Zhang, Y. Li, P.X., S.L., Y. Zhou, J.S., C.Y., Y. Liang, M.S.).
  • Liangzhu Laboratory (W.X., S.Z., A.L., Jin Zhang), Zhejiang University School of Medicine, Hangzhou, China.
  • Center for Stem Cell and Regenerative Medicine, Department of Basic Medical Sciences, and Bone Marrow Transplantation Center of the First Affiliated Hospital (W.X., S.Z., A.L., Jin Zhang), Zhejiang University School of…
  • Institute of Hematology, Zhejiang University, Hangzhou, China (W.X., S.Z., A.L., Jin Zhang).
  • Center of Gene and Cell Therapy and Genome Medicine of Zhejiang Province, Hangzhou, China (W.X., S.Z., A.L., Jin Zhang).

ORCID-Profile: Jiawan Wang, Heng Du, Wanrun Xie, Jinmiao Bi, Hao Zhang, Xu Liu, Jiahe Zhang, Siqi Liu, Jianghua Shen, Jingdong Wu, Yihong Cai, Chaofan Yang, Yingxin Liang, Yang Zhao, Moshi Song

Zitieren

APA

Wang, J., Du, H., Xie, W., Bi, J., Zhang, H., Liu, X., Wang, Y., Zhang, S., Lei, A., He, C., Yuan, H., Zhang, J., Li, Y., Xu, P., Liu, S., Zhou, Y., Shen, J., Wu, J., Cai, Y., …, & Song, M. (2024). CAR-Macrophage Therapy Alleviates Myocardial Ischemia-Reperfusion Injury. Circulation Research, 135(12), 1161-1174. https://doi.org/10.1161/circresaha.124.325212

Vancouver

Wang J, Du H, Xie W, Bi J, Zhang H, Liu X, et al. CAR-Macrophage Therapy Alleviates Myocardial Ischemia-Reperfusion Injury. Circulation Research. 2024;135(12):1161-1174. doi:10.1161/circresaha.124.325212

BibTeX
@article{Wang2024,
  author = {Wang, Jiawan and Du, Heng and Xie, Wanrun and Bi, Jinmiao and Zhang, Hao and Liu, Xu and Wang, Yuhan and Zhang, Shaolong and Lei, Anhua and He, Chuting and Yuan, Hailong and Zhang, Jiahe and Li, Yujing and Xu, Pengfei and Liu, Siqi and Zhou, Yanan and Shen, Jianghua and Wu, Jingdong and Cai, Yihong and Yang, Chaofan and Li, Zeya and Liang, Yingxin and Zhao, Yang and Zhang, Jin and Song, Moshi},
  title = {CAR-Macrophage Therapy Alleviates Myocardial Ischemia-Reperfusion Injury},
  journal = {Circulation Research},
  year = {2024},
  volume = {135},
  number = {12},
  pages = {1161--1174},
  doi = {10.1161/circresaha.124.325212}
}
Kostenlos starten →